MDR1基因、CD269基因在老年骨髓瘤患者中的表达及与疾病预后的相关性
|
摘要
目的探讨MDR1基因、CD269基因在老年骨髓瘤患者中的表达及与疾病预后的相关性。方法采用定量PCR法对2012-2013年我院收治的老年骨髓瘤患者体内MDR1基因与CD269基因表达进行检查,并分析表达结果与临床病理特征及预后的关系。结果 34例老年骨髓瘤患者血清及骨髓液样本中MDR1基因与CD269基因表达明显高于健康者。不同年龄、性别患者体内中MDR1基因与CD269基因表达差异无统计学意义,而出现肿瘤复发、Charlson指数(CCI)评分较高、生存时间较短的患者体内MDR1基因与CD269基因表达差异具有统计学意义(P <0.05)。其中MDR1基因与CD269基因表达越高的患者CCI评分≥5、生存时间越短、越易出现肿瘤复发。MDR1基因与CD269基因表达量与CCI评分呈正相关(r=0.786,P <0.001;r=0.825,P <0.001)。结论 MDR1基因、CD269基因参与骨髓瘤细胞的增殖与存活,影响骨髓瘤疾病预后,有望成为骨髓瘤未来诊断以及治疗的潜在靶标。
Objective To investigate the expressions of MDR1 gene and CD269 gene in elderly myelomapatients and their correlation with disease prognosis. Methods RT-PCR was used to determine the expressions ofMDR1 and CD269 in elderly myeloma patients in hospital from 2012 to 2013.The associations between the expres-sions of MDR1 and CD269 in elderly myeloma patients and clinical and pathological features and prognosis wereanalyzed. Results The expressions of MDR1 gene and CD269 gene in serum and bone marrow samples of 34 elderlypatients with myeloma were significantly higher than those of healthy people. There were no significant differencesin the expressions of MDR1 gene and CD269 gene between different ages and genders. Patients with higher expres-sions of MDR1 gene and CD269 gene have higher tumor recurrence,with Clarson index(CCI)score more than 5 and shorter survival time(P < 0.05,respectively). The expressions of MDR1 and CD269 were positively correlatedwith CCI score(r = 0.786,P < 0.01;r = 0.825,P < 0.01). Conclusion MDR1 gene and CD269 gene are involvedin the proliferation and survival of myeloma cells,affecting the prognosis of myeloma diseases,which are expectedto be potential targets for future diagnosis and treatment of myeloma.
Objective To investigate the expressions of MDR1 gene and CD269 gene in elderly myelomapatients and their correlation with disease prognosis. Methods RT-PCR was used to determine the expressions ofMDR1 and CD269 in elderly myeloma patients in hospital from 2012 to 2013.The associations between the expres-sions of MDR1 and CD269 in elderly myeloma patients and clinical and pathological features and prognosis wereanalyzed. Results The expressions of MDR1 gene and CD269 gene in serum and bone marrow samples of 34 elderlypatients with myeloma were significantly higher than those of healthy people. There were no significant differencesin the expressions of MDR1 gene and CD269 gene between different ages and genders. Patients with higher expres-sions of MDR1 gene and CD269 gene have higher tumor recurrence,with Clarson index(CCI)score more than 5 and shorter survival time(P < 0.05,respectively). The expressions of MDR1 and CD269 were positively correlatedwith CCI score(r = 0.786,P < 0.01;r = 0.825,P < 0.01). Conclusion MDR1 gene and CD269 gene are involvedin the proliferation and survival of myeloma cells,affecting the prognosis of myeloma diseases,which are expectedto be potential targets for future diagnosis and treatment of myeloma.
引文
[1] LATIF A,KAPOOR V,SIPRA Q U A R,et al. Disease mile-stones through bibliometric analysis of the top 100 cited articles inmultiple myeloma[J]. Cureus,2018,10(4):e2438-e2443.
[2] SALVINI M,D′AGOSTINO M,BONELLO F,et al. Determin-ing treatment intensity in elderly patients with multiple myelo-ma.[J]. Expert Rev Anticancer Ther,2018,6(13):1-14.
[3] BASMACI C,PEHLIVAN M,TOMATIR A,et al. Effects ofTNFα,NOS3,MDR1 Gene Polymorphisms on Clinical Parame-ters,Prognosis and Survival of Multiple Myeloma Cases.[J].Asian Pac J Cancer Prev,2016,17(3):1009-1014.
[4] GHERMEZI M,LI M,VARDANYAN S,et al. Serum B-cellmaturation antigen:a novel biomarker to predict outcomes formultiple myeloma patients[J]. Haematologica,2017,102(4):785-795.
[5] JIMBO K,YOKOYAMA K,OGAWA M,et al. Autologous pe-ripheral blood stem cell transplantation for double-refractory my-eloma with K-RAS and N-RAS mutations[J]. Rinsho Ketsue-ki,2017,58(12):2380-2385.
[6] PARMO-CABA?AS M,MOLINA-ORTIZ I,MATíAS-ROMáNS,et al. Role of metalloproteinases MMP-9 and MT1-MMP inCXCL12-promoted myeloma cell invasion across basement mem-branes.[J]. J Pathol,2006,208(1):108-118.
[7] VAJDOVICH P,KOLTAI Z,D?KAY V,et al. Evaluation ofPgp(MDR1)immunohistochemistry in canine lymphoma-prog-nostic and clinical aspects[J]. Acta Vet Hung,2018,66(2):309-328.
[8] SHEN X,WANG M,GUO Y,et al. The Correlation BetweenNon-Hodgkin Lymphoma and Expression Levels of B-Cell Acti-vating Factor and Its Receptors[J]. Adv Clin Exp Med,2016,25(5):837-844.
[9] AUNER HW,GARDERET L,KR?GER N,et al. Autologoushaematopoietic cell transplantation in elderly patients with multi-ple myeloma[J]. Br J Haematol,2015,171(4):453-462.
[10] YANG C C,CHEN P C,HSU C W,et al. Validity of the age-adjusted charlson comorbidity index on clinical outcomes for pa-tients with nasopharyngeal cancer post radiation treatment:a 5-year nationwide cohort study[J]. PLoS One,2015,10(1):e0117323-e0117327.
[11] ZHENG C,ZHANG X,ZHAO Z,et al. Selective BindingBAFF/APRIL by the In and Outside Conservative Region of BC-MA[J]. Protein Pept Lett,2017,24(6):489-494.
[12]徐光,班永宏,鞠少卿,等. JNK信号通路活化与BCMA表达对MM细胞的作用研究[J].国际检验医学杂志,2016,37(22):3117-3122.
[13]刘玉霞,胡国瑜,袁朝晖,等. CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,11(2):58-61.
[14] ZHANG Y,LI Y,WANG H,et al. Correlation of MDR1 genepolymorphism with propofol combined with remifentanil anesthe-sia in pediatric tonsillectomy[J]. Oncotarget,2017,9(29):20294-20303.
[15] KALITIN N N,CHERNYKH Y B,BURAVTSOVA I V. Com-parative Analysis of Quantitative Parameters of Expression of theRetinoic Acid Nuclear Receptor RARαGene and APE1/YB-1/MDR1 Pattern Genes in Patients with Newly Detected MultipleMyeloma.[J]. Bull Exp Biol Med,2017,164(1):90-94.
[2] SALVINI M,D′AGOSTINO M,BONELLO F,et al. Determin-ing treatment intensity in elderly patients with multiple myelo-ma.[J]. Expert Rev Anticancer Ther,2018,6(13):1-14.
[3] BASMACI C,PEHLIVAN M,TOMATIR A,et al. Effects ofTNFα,NOS3,MDR1 Gene Polymorphisms on Clinical Parame-ters,Prognosis and Survival of Multiple Myeloma Cases.[J].Asian Pac J Cancer Prev,2016,17(3):1009-1014.
[4] GHERMEZI M,LI M,VARDANYAN S,et al. Serum B-cellmaturation antigen:a novel biomarker to predict outcomes formultiple myeloma patients[J]. Haematologica,2017,102(4):785-795.
[5] JIMBO K,YOKOYAMA K,OGAWA M,et al. Autologous pe-ripheral blood stem cell transplantation for double-refractory my-eloma with K-RAS and N-RAS mutations[J]. Rinsho Ketsue-ki,2017,58(12):2380-2385.
[6] PARMO-CABA?AS M,MOLINA-ORTIZ I,MATíAS-ROMáNS,et al. Role of metalloproteinases MMP-9 and MT1-MMP inCXCL12-promoted myeloma cell invasion across basement mem-branes.[J]. J Pathol,2006,208(1):108-118.
[7] VAJDOVICH P,KOLTAI Z,D?KAY V,et al. Evaluation ofPgp(MDR1)immunohistochemistry in canine lymphoma-prog-nostic and clinical aspects[J]. Acta Vet Hung,2018,66(2):309-328.
[8] SHEN X,WANG M,GUO Y,et al. The Correlation BetweenNon-Hodgkin Lymphoma and Expression Levels of B-Cell Acti-vating Factor and Its Receptors[J]. Adv Clin Exp Med,2016,25(5):837-844.
[9] AUNER HW,GARDERET L,KR?GER N,et al. Autologoushaematopoietic cell transplantation in elderly patients with multi-ple myeloma[J]. Br J Haematol,2015,171(4):453-462.
[10] YANG C C,CHEN P C,HSU C W,et al. Validity of the age-adjusted charlson comorbidity index on clinical outcomes for pa-tients with nasopharyngeal cancer post radiation treatment:a 5-year nationwide cohort study[J]. PLoS One,2015,10(1):e0117323-e0117327.
[11] ZHENG C,ZHANG X,ZHAO Z,et al. Selective BindingBAFF/APRIL by the In and Outside Conservative Region of BC-MA[J]. Protein Pept Lett,2017,24(6):489-494.
[12]徐光,班永宏,鞠少卿,等. JNK信号通路活化与BCMA表达对MM细胞的作用研究[J].国际检验医学杂志,2016,37(22):3117-3122.
[13]刘玉霞,胡国瑜,袁朝晖,等. CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,11(2):58-61.
[14] ZHANG Y,LI Y,WANG H,et al. Correlation of MDR1 genepolymorphism with propofol combined with remifentanil anesthe-sia in pediatric tonsillectomy[J]. Oncotarget,2017,9(29):20294-20303.
[15] KALITIN N N,CHERNYKH Y B,BURAVTSOVA I V. Com-parative Analysis of Quantitative Parameters of Expression of theRetinoic Acid Nuclear Receptor RARαGene and APE1/YB-1/MDR1 Pattern Genes in Patients with Newly Detected MultipleMyeloma.[J]. Bull Exp Biol Med,2017,164(1):90-94.